Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s Esophagus

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 436-443

  Schneider, Jennifer L ^a   Zhao, Wei K ^a   Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

Barrett s esophagus; Chemoprevention; Esophageal cancer; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION DYNAMICS; PRIORITY JOURNAL; RISK FACTOR; CALIFORNIA; CELL PROTECTION; DRUG ADMINISTRATION; MIDDLE AGED; ODDS RATIO; PROTECTION; RISK ASSESSMENT; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CALIFORNIA; CASE-CONTROL STUDIES; CYTOPROTECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84921794721     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3349-2     Document Type: Article

References (41)

1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–128.
2. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.
3. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338.
4. Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:1795–1800.
5. Reid BJ, Barrett MT, Galipeau PC, et al. Barrett’s esophagus: ordering the events that lead to cancer. Eur J Cancer Prev. 1996;5:57–65.
6. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the west. Gastroenterology. 2002;122:588–590.
7. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952.
8. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56.
9. Aspirin reduces esophageal-cancer risk in people with most-aggressive form of Barrett’s esophagus; 2007. http://www.sciencedaily.com/releases/2007/02/070227105902.htm. Accessed 21 Sept 2011.
10. Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–4982.
11. Jayaprakash V, Menezes RJ, Javle MM, et al. Regular aspirin use and esophageal cancer risk. Int J Cancer. 2006;119:202–207.
12. Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452.
13. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.
14. Wang F, Lv ZS, Fu YK. Nonsteroidal anti-inflammatory drugs and esophageal inflammation—Barrett’s esophagus—adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2010;1:1–10.
15. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 2005;26:565–570.
16. Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:722–727.
17. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–710.
18. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus Gastroenterology. 2007;133:34–41; quiz 311.
19. Rothman KJGS. Modern Epidemiology. Phildadeplphia, PA: Lippincott-Raven; 1998.
20. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:539–547.
21. Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care. 2005;43:34–43.
22. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res. 2001;36:180–193.
23. Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int J Cancer. 2012;130:2407–2416.
24. Kuo CJ, Lin CH, Liu NJ, et al. Frequency and risk factors for Barrett’s esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci. 2010;55:1337–1343.
25. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc. 2006;54:1537–1542.
26. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett’s esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009;43:907–914.
27. Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340–1350.
28. Pasricha PJ, Bedi A, O’Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 1995;109:994–998.
29. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–1619.
30. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–639.
31. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–266.
32. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology. 2002;122:1101–1112.
33. Esquivias P, Morandeira A, Escartin A, et al. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol. 2012;18:4866–4874.
34. Tsibouris P, Vlachou E, Isaacs P. Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus. World J Gastrointest Pharmacol Ther. 2014;5:27–39.
35. Nalamachu S, Pergolizzi J, Raffa R, Lakkireddy D, Taylor RJ. Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf. 2014;13:903–917.
36. Bavry A, Thomas F, Allison M, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women’s health initiative. Circ Cardiovasc Qual Outcomes. 2014;7:603–610.
37. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97–102.
38. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74–77.
39. 2005 Kaiser Permanente Adult Member Health Survey Report for the Northern California Region Membership; 2007. http://www.dor.kaiser.org/external/DORExternal/mhs/2005_ncal_report.aspx. Accessed 7 Mar 2013.
40. Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16:2090–2096.
41. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.